
Pick the Best Antibody for Improved Clinical Success!






NON-FED, NON-OPTIMIZED SHAKER FLASK



FED-BATCH CULTURE SHAKER FLASK



SUREvariant SCREENING

Up to 500 variants screened for **ACTIVITY** and **EXPRESSION** at the same time

SUREpools

Typical MAb expression levels up to 500 mg/L 5 weeks from transfection


SUREclones

Typical fed-batch expression levels > 2 grams of protein 5 weeks post screening

Selexis' SUREvariant Screening™ accelerates and improves outcomes from displayed library selection campaigns by reducing the time and the number of steps to identify

potential lead candidates. The SUREvariant Screening™ platform used at Selexis can generate panels of up to 500 CHO-M cell pools (SURE*pools*™), each expressing different protein variants. Typical expression levels in the supernatants (SURE*natants*™) for MAbs vary between 50-500 mg/L. The SURE*natants*™ containing the recombinant proteins expressed with mammalian posttranslational modifications can be readily assessed for activity. Subsequently, Selexis SURE*pools*™ top candidates can be banked (stored) and then reused for further assays. The top SURE*pool*™ candidate is transferred to the Selexis' SURE Cell Line™ Development platform to generate a high producing clonal cell line ready for cGMP manufacturing. The entire process from SURE variant Screening™ to the clonal cell line can be as short as 14 weeks. Selexis SUREvariant Screening™ can reduce your development costs by over \$500,000 per clinical candidate!

Screen your lead antibodies using the Selexis SUREvariant Scrrening™ program in weeks!



NORTH AMERICA

Selexis Inc. 197 Boston Post Road West - Suite 271 Marlborough, MA 01752 info@selexis.com



EUROPE Selexis SA 18 chemin des Aulx 1228 Plan-les-Ouates Switzerland info@selexis.com